Haemophilus influenzae type b Conjugate Vaccine
- All children should be vaccinated, beginning routinely at 2 months of age.
- Recommended to be administered before splenectomy, two weeks if possible.
- Hiberix is a Haemophilus influenzae type b vaccine FDA indicated for use as a booster in children aged 15 months through 4 years
Hepatitis B, Haemophilus influenza type b
5-7.5-125 per 0.5 ml
$52.58 per vial
Haemophilus influenzae type b (monovalent Hib vaccine)
10 mcg/0.5 ml
$26.50 per vial
Haemophilus influenza type b conjugate vaccine.
10 mcg/ 0.5 mL
$26.49 per vial
15-20-5-10 per 0.5 ml
$83.00 per vial
*Prices represent cost per unit specified, are representative of "Average Wholesale Price" (AWP).
^Dosage is indicated in mg unless otherwise noted.
PATHOGEN DIRECTED PROTECTION
Comvax: infants born to HBsAg negative mothers should be vaccinated with three 0.5 mL IM doses, ideally at 2, 4, and 12-15 months of age. Infants born to HBsAg-positive mothers should receive Hepatitis B Immune Globulin and Hepatitis B Vaccine at birth and should complete the hepatitis B vaccination series.
ActHIB: Infants 2 to 14 months of age should receive a 0.5 mL dose of vaccine ideally beginning at 2 months of age followed by a 0.5 mL dose 2 months later. When the primary two-dose regimen is completed before 12 months of age, a booster dose is required.
Booster dose in infants completing the primary two-dose regimen before 12 months of age, a booster dose with Hiberix (0.5 mL) should be administered at 12 to 15 months of age, but not earlier than 2 months after the second dose.
ADVERSE DRUG REACTIONS
- Generally well tolerated with adverse reactions comparable to placebo
- Fever (3%-4.3% after second dose)
- Injection site reaction (erythema in 0.7%-1.2%, swelling and induration in 0.9%-3.7% after the second dose)
- May be co-administered with DTP, DTaP, poliovirus vaccine live oral (OPV), MMR, hepatitis B vaccine and inactivated poliovirus vaccine (IPV).
- Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to vaccines.
- Hypersensitivity to components of the vaccine.
An antibody serum level of >1.0 mcg/ml following vaccination corresponds with long-term protection against H. influenzae type b disease. ActHIB vaccine induced, on average anti-PRP levels >1.0 mcg/mL in 90% of infants after the primary series and in more than 98% of infants after a booster dose.
- Efficacy of 93% reported in randomized placebo controlled trial. Observational studies reported an efficacy rate of up to 100%.
Basis for recommendation
- Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep 40:1, 1991 [PMID:1899280]
Comment: ACIP recommendations
Haemophilus influenzae (Hib) vaccine is a sample topic found in Johns Hopkins Guides.
To find other Johns Hopkins Guides topics please log in or purchase a subscription.